Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis

Sponsor
Pfizer
Study ID
NCT04424303
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an observational prospective study with two years of follow-up, designed to evaluate the effectiveness of tofacitinib in patients with moderate to severe ulcerative colitis in French clinical practice

Key Dates

Start date
Dec 4, 2020
Status verified
Jan 2026
Primary completion
Dec 8, 2025
Completion
Dec 8, 2025

Study Design

Enrollment
152 participants (actual)

Arms

  • Arm: Patients prescribed tofacitinib
    Patients with a confirmed diagnosis of moderate to severe ulcerative colitis initiating tofacitinib as per the French summary of product characteristics (SmPC).

Primary Outcome Measure

Proportion of patients with clinical benefit one year after initiation of tofacitinib treatment. [ Time Frame: Week 52 ]

Related Studies